Allakos Inc.

Dren Bio, Inc.

Kalobios Pharmaceuticals, Inc.

Nenad Tomasevic

Christopher Robert Bebbington

Rustom Falahati

Jason Williams

Bradford Andrew Youngblood

Ruo Shi Shi

Wouter Korver

Geoffrey T Yarranton

Kenneth Luehrsen

Mark Baer

Varghese Palath

David Martinez

John Leung

Andrew P Ah Young-chapon

Xiaodi Deng

Panagiotis Fotakis

Carolina Rita Sousa Fernandes

Swathi Sujatha-Bhaskar

David John Matthews

Suzy El Bader

The present disclosure relates to antibodies that bind human Dectin-1, multispecific (e.g., bispecific) binding molecules, and methods of use and production related thereto.

Anti-Dectin-1 antibodies and methods of use thereof

The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function.

Anti-Siglec-7 antibodies having reduced effector function

The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.

Anti-CD94 antibodies and methods of use thereof

The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.

Anti-Siglec-7 antibodies for the treatment of cancer

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis

The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.

Methods and compositions for treating fibrotic diseases

The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.

Methods and compositions for treating systemic mastocytosis

The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.

Methods and compositions for treating Siglec-8 associated diseases

The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.

Anti-Siglec-8 antibodies and methods of use thereof

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Growing community of inventors

Foster City, CA, United States of America

Nenad Tomasevic